Standard of Care for HCV/HIV-Coinfected Patients

References

• Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992; 9: 249–304.
   Google Scholar
• Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977; 252: 3578–81.
   Google Scholar
• Alberti A, Benvegnù L. Management of hepatitis C. J Hepatol 2003; 38 Suppl 1: S104–18.
   Google Scholar
• Silva M, et al. Comparison of peginterferon-α2a and peginterferon-α2b pharmacokinetics and pharmacodynamic in COMPARE, a randomized, prospective, blinded trial. Abstract 68, 55° Annual Meeting of American Association for the Study of Liver Diseases (AASLD). October 29-November 2, 2004, Boston, MA (USA).
   Google Scholar
• Leaman D, Brassard D, Cox S, et al. Pegylated interferon alpha 2b and pegylated interferon alpha 2a exhibit different anti-proliferative activity in vitro. Hepatology 2002; 36: 547A.
   Google Scholar
• Caliceti P. Pharmacokinetics of pegylated interferons: what is misleading? Dig Liver Dis 2004; 36 Suppl 3: S334–9.
   Google Scholar
• Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12: 195–202.
   Google Scholar
• Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of pegylated recombinant IFNalpha2b. J Interferon Cytokine Res 2001; 21: 1103–15.
   Google Scholar
• Grace MJ, Lee S, Bradshaw S, et al. Site of pegylation and polyethylene glycol molecule size attenuate interferonalpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J Biol Chem 2005; 280: 6327–36.
   Google Scholar
• Kozlowski A, Harris JM. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release 2001; 72: 217–24.
   Google Scholar
• Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556–67.
   Google Scholar
• Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711–9.
   Google Scholar
• Gaertner HF, Offord RE. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjug Chem 1996; 7: 38–44.
   Google Scholar
• Miglioresi L, Riva E, Antonelli G, et al. Localization of hepatitis C virus in gastrointestinal mucosa: a possible reservoir for relapse. Hepatology 2003; 38: 775.
   Google Scholar
• Hu Y, Shahidi A, Park S, et al. Detection of extrahepatic hepatitis C virus replication by a novel, highly sensitive, single-tube nested polymerase chain reaction. Am J Clin Pathol 2003; 119: 95–100.
   Google Scholar
• Carrozzo M, Quadri R, Latorre P, et al. Molecular evidence that the hepatitis C virus replicates in the oral mucosa. J Hepatol 2002; 37: 364–9.
   Google Scholar
• Yan FM, Chen AS, Hao F, et al. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World J Gastroenterol 2000; 6: 805–811.
   Google Scholar
• Bailon P, et al. Polyethylene glicol-conjugated pharmaceutical proteins. Pharm Sci Tech Today 1998; 1: 352–56.
   Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65.
   Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
   Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55.
   Google Scholar
• Zeuzem S, et al. International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alpha-2a (40 kD) (Pegasys) and ribavirin (Copegus). Hepatology 2003; 38 (Suppl 1): Abs 106.
   Google Scholar
• Lamb MW, Martin NE. Weight-based versus fixed dosing of peginterferon (40kDa) alpha-2a. Ann Pharmacother 2002; 36: 933–5.
   Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alpha-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–72.
   Google Scholar
• Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alpha-2a (40KD). J Hepatol 2002; 37: 500–6.
   Google Scholar
• FDA analysis of the Fried and Hadziyannis study. FDA briefing document. http://www.fda.gov/ohrms/dockets/ac/02/briefing/3909B1_02_FDA%20briefing%20%package%20.doc
   Google Scholar
• Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651–62.
   Google Scholar
• Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778–809.
   Google Scholar
• Grace MJ, Cutler D. Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antivir Chem Chemother 2004; 15: 287–97.
   Google Scholar
• Luise S, Bernardinello E, Cavalletto L, et al. Kinetic of virological response during peg-IFNS in chronic hepatitis C. 39th Annual Meeting of European Association for the Study of the Liver (EASL). April 14-18, 2004, Berlin, Germany. Abstract 490.
   Google Scholar
• Cesario K, Khandwala F, Edwards K, et al. Impact of obesity on degree of liver disease and response to therapy in patients with chronic hepatitis C virus infection. J Hepatol 2005; 42 (Suppl 2): 201.
   Google Scholar
• Lim JK, Imperial JC, Keeffe EB. Retreatment of chronic hepatitis C virus infection. Rev Gastroenterol Disord 2004; 4: 97–103.
   Google Scholar
• Gutfreund KS, Bain VG. Chronic viral hepatitis C: management update. CMAJ 2000; 162: 827–33.
   Google Scholar
• Craxì A, Licata A. Clinical trial results of peginterferons in combination with ribavirin. Semin Liver Dis 2003; 23 (Suppl 1): 35–46.
   Google Scholar
• Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alpha-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015–23.
   Google Scholar
• Poynard T et al. for the EPIC3 Study Group. High early viral response (EVR) with Peg-Intron/Rebetol (PR) weight based dosing (WBD) in previous interferon/ribavirin HCV treatment failures; early results of the EPIC3 trial. 55° Annual Meeting of American Association for the Study of Liver Diseases (AASLD). October 29- November 2, 2004, Boston, MA (USA). Abstract 170.
   Google Scholar
• Poynard T, Schiff E, Terg R, et al. Sustained virologic response (SVR) in the EPIC3 trial: week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving peg-intron/rebetol (PR) weight based dosing (WBD). J Hepatol 2005; 42 (Suppl 2): 40
   Google Scholar
• Afdhal N, Freilich B, Levine R, et al. Colchicine versus peg-intron long-term (COPILOT) trial: interim analysis of clinical outcomes at year 2. 55° Annual Meeting of American Association for the Study of Liver Diseases (AASLD). October 29-November 2, 2004, Boston, MA (USA). Abstract 171.
   Google Scholar
• Marcellin P et al. REtreatment with PEgasys® in pATients not responding to prior peginterferon alpha-2b/ribavirin (RBV) combination therapy - efficacy analysis of the 12- week induction period of the REPEAT study. Abstract 72557.56th annual meeting of the American Association for the Study of Liver Diseases (56th AASLD). November 11-15, 2005. San Francisco, CA.
   Google Scholar
• Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992–1002.
   Google Scholar
• Rockstroh JK, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996; 91: 2563–8.
   Google Scholar
• Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183: 134–7.
   Google Scholar
• Garcia-Samaniego J, Rodriguez M, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179–83.
   Google Scholar
• Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1–5.
   Google Scholar
• Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14: 949–53.
   Google Scholar
• Martin-Carbonero L, Benhamou Y, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38: 128–33.
   Google Scholar
• Melvin DC, Lee JK, Belsey E, et al. The impact of coinfection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS 2000; 14: 463–5.
   Google Scholar
• Soriano V, Nuñez M, Camino N, et al. Treatment of hepatitis C in HIV-infected patients. Hepatology Rev 2004; 2: 59–71.
   Google Scholar
• Fleming CA, Craven DE, Thornton D, et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36: 97–100.
   Google Scholar
• Rauch A, Egger M, Reichen J, et al. Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin. J Acquir Immune Defic Syndr 2005; 38: 238–40.
   Google Scholar
• Fultz SL, Justice AC, Butt AA, et al. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis 2003; 36: 1039–46.
   Google Scholar
• Hall CS, Charlebois ED, Hahn JA, et al. Hepatitis C virus infection in San Francisco’s HIV-infected urban poor. J Gen Intern Med 2004; 19: 357–65.
   Google Scholar
• Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23: 585–91.
   Google Scholar
• Mauss S, Klinker H, Ulmer A, et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 1998; 26: 16–9.
   Google Scholar
• Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004; 39: 880–90.
   Google Scholar
• Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370–81.
   Google Scholar
• Vento S, Di Perri G, Cruciani M, et al. Rapid decline of CD4+ cells after IFN alpha treatment in HIV-1 infection. Lancet 1993; 341: 958–9.
   Google Scholar
• Pesce A, Taillan B, Rosenthal E, et al. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet 1993; 341: 1597.
   Google Scholar
• Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS 2004; 18: 1–12.
   Google Scholar
• Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998; 280: 2088–93.
   Google Scholar
• Spinzi G, Minoli G. To biopsy or not to biopsy. Hepatology 2001; 34: 438.
   Google Scholar
• Andriulli A, Mangia A, Niro G, Caturelli E. To biopsy or not to biopsy. Hepatology 2001; 34: 438–9.
   Google Scholar
• Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36 (5 Suppl 1): S152–60.
   Google Scholar
• Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705–13.
   Google Scholar
• Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48–54.
   Google Scholar
• Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343–50.
   Google Scholar
• Tossing G. Management of chronic hepatitis C in HIVco-infected patients—results from the First International Workshop on HIV and Hepatitis Co-infection, 2nd-4th December 2004, Amsterdam, Netherlands. Eur J Med Res 2005; 10: 43–5.
   Google Scholar
• Chung R, Andersen J, Voberding P, et al. A randomised controlled trial of peginterferon alpha-2a + ribavirin versus interferon alpha-2a + ribavirin for chronic hepatitis C virus infection in HIV-coinfected persons: follow-up results of ACTG A5071. 11th Conference on retroviruses and Opportunistic Infections. San Francisco 2004 (Abs 110).
   Google Scholar
• Torriani FJ et al. Final Results of APRICOT: A Randomized, Partially Blinded, International Trial Evaluating Peginterferon-alpha-2a + Ribavirin vs Interferon-alpha-2a + Ribavirin in the Treatment of HCV in HIV/HCV Co-infection. Abstract 112 (oral). Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (11th CROI). February 8-12, 2004. San Francisco, CA.
   Google Scholar
• Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alpha-2b vs standard interferon alpha-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839–48.
   Google Scholar
• Laguno M, Murillas J, Blanco JL, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27–36.
   Google Scholar
• Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645–52.
   Google Scholar
• Torriani FJ, Ribeiro RM, Gilbert TL, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003; 188: 1498–507.
   Google Scholar
• Ballesteros AL, Franco S, Fuster D, et al. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV coinfection: indications for the investigation of new treatment approaches. AIDS 2004; 18: 59–66.
   Google Scholar
• Moreno L, Quereda C, Moreno A, et al. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004; 18: 67–73.
   Google Scholar
• Soriano V, Nunez M, Camino N, et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 2004; 9: 505–9.
   Google Scholar
• NIH Consensus Development Conference Statement: management of hepatitis C. Gastroenterology 2002; 123: 2082–99.
   Google Scholar
• Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferonalpha therapy. Science 1998; 282: 103–7.
   Google Scholar
• Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36 (5 Suppl 1): S65–73.
   Google Scholar
• Soriano V, Perez-Olmeda M, Rios P, et al. Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Res Hum Retroviruses 2004; 20: 351–3.
   Google Scholar
• Brouwer JT, Nevens F, Bekkering FC, et al. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol 2004; 40: 689–95.
   Google Scholar
• The ECC Jury. Short Statement of the first European consensus conference on the treatment of chronic hepatitis C and B co-infected patients. 1-2 March, 2005, Paris, France. J Hepatol 2005; 42: 615–624.
   Google Scholar